ERBB2 and hepatocellular carcinoma: While biliary tract cancers and specifically, extrahepatic cholangiocarcinomas, often harbor overexpression of HER2, and thus have demonstrated response to various anti–HER2 regimens [12], this is an incredibly rare occurrence in HCC.